Not All Missed Doses Are the Same: Sustained NNRTI Treatment Interruptions Predict HIV Rebound at Low-to-Moderate Adherence Levels by Parienti, Jean-Jacques et al.
Not All Missed Doses Are the Same: Sustained NNRTI
Treatment Interruptions Predict HIV Rebound at Low-to-
Moderate Adherence Levels
Jean-Jacques Parienti
1,2*, Moupali Das-Douglas
3,V e ´ronique Massari
2, David Guzman
5, Steven G.
Deeks
3, Renaud Verdon
1, David R. Bangsberg
4
1Clinical Research and Biostatistics, and Infectious Diseases Departments, Co ˆte de Nacre University Hospital, Caen, France, 2Pierre et Marie Curie University Paris 6, UMR
S707 and INSERM U707, Paris, France, 3Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, and The Positive Health Program, San Francisco
General Hospital, University of California San Francisco, San Francisco, California, United States of America, 4Partners AIDS Research Center, Massachusetts General
Hospital, Harvard University, Boston, Massachusetts, United States of America, 5Epidemiology and Prevention Interventions Center, Division of Infectious Diseases,
University of California San Francisco, San Francisco, California, United States of America
Abstract
Background: While the relationship between average adherence to HIV potent antiretroviral therapy is well defined, the
relationship between patterns of adherence within adherence strata has not been investigated. We examined medication
event monitoring system (MEMS) defined adherence patterns and their relation to subsequent virologic rebound.
Methods and Results: We selected subjects with at least 3-months of previous virologic suppression on a non-nucleoside
reverse transcriptase inhibitor (NNRTI)-based regimen from two prospective cohorts in France and North America. We
assessed the risk of virologic rebound, defined as HIV RNA of .400 copies/mL according to several MEMS adherence
measurements. Seventy two subjects were studied, five of them experienced virologic rebound. Subjects with and
without virologic rebound had similar baseline characteristics including treatment durations, regimen (efavirenz vs
nevirapine), and dosing schedule. Each 10% increase in average adherence decreased the risk of virologic rebound
(OR=0.56; 95% confidence interval (CI) [0.37, 0.81], P,0.002). Each additional consecutive day off therapy for the longest
treatment interruption (OR=1.34; 95%CI [1.15, 1.68], P,0.0001) and each additional treatment interruption for more than 2
days (OR=1.38; 95%CI [1.13, 1.77], P,0.002) increased the risk of virologic rebound. In those with low-to-moderate
adherence (i.e. ,80%), treatment interruption duration (16.2 days versus 6.1 days in the control group, P,0.02), but not
average adherence (53.1% vs 55.9%, respectively, P=0.65) was significantly associated with virologic rebound.
Conclusions: Sustained treatment interruption may pose a greater risk of virologic rebound on NNRTI therapy than the
same number of interspersed missed doses at low-to-moderate adherence.
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Introduction
Adherence to HIV antiretroviral therapy is the strongest
predictor of virologic suppression[1,2], HIV drug resistance[3],
disease progression and death[4,5]. While treatment with
unboosted protease inhibitors (PI) requires near perfect adherence
for virologic suppression[1], the introduction of more potent non-
nucleoside reverse transcriptase inhibitors (NNRTI) and ritonavir
boosted PI therapy has lead to reliable virologic suppression at
moderate levels of adherence for most, but not all patients[6–9].
Because not all patients with moderate adherence are
suppressed, we asked if all missed doses are the same. Specifically,
we hypothesized that patterns of adherence in addition to average
adherence may be an important determinant of incomplete viral
suppression. We focused on NNRTI based regimens because these
drugs are the cornerstone for most first line regimens world-wide.
Because the NNRTIs are potent and have a very long-half life in
vivo, we hypothesized that once viral suppression was achieved, a
sustained treatment interruption rather than frequent missed doses
would be associated with virologic failure.
To test this hypothesis, we analyzed prospectively collected data
from NNRTI treated individuals who achieved an initial virologic
response during adherence monitoring with electronic medication
monitors. Electronic medication monitors measure patterns of
missed doses with a time-date record of pill bottle opening
behaviour. The objective of this study was to identify adherence
patterns predictive of virologic rebound on NNRTI-based
antiretroviral therapy. We examined the temporal association
between average adherence, treatment interruptions and subse-
quent viral rebound in all subjects, but in particular, subjects with
,80% adherence because they are at highest risk for virologic
rebound[7,10].
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Patients Population and Study Design
We conducted a case-control study of NNRTI treated patients
nested in two prospective observational cohorts: the Posology of
Nevirapine (POSOVIR) Study and the Research in Access to Care
(REACH) Cohort. POSOVIR is a randomized study of once
versus twice daily nevirapine at 4 teaching medical institutions in
France[10]. The REACH cohort is an observational study of HIV
positive homeless and marginally housed individuals in San
Francisco[7]. Written informed consent was obtained from all
participants for adherence monitoring, monthly phlebotomy, and
assessment of viral load and CD4 cell count. The University of
Caen Institutional Review Board (POSOVIR) and the University
of California, San Francisco Committee on Human Subjects
Research (REACH) approved all study procedures. We selected
NNRTI-based treated individuals with HIV RNA level (VL) ,400
copies/ml after at least 3 months of treatment and monitored
adherence with the AARDEX Medication Event Monitoring
System (MEMS). Virologic rebound was defined as VL $400
copies/ml at any point during adherence monitoring.
Adherence Monitoring and Definitions
Adherence was prospectively measured using the Medication
Event Monitoring System (MEMS) 6 caps (AARDEX Ltd,
Switzerland or Union City, Ca., USA). Individuals with no
MEMS events for .15 days immediately prior to virologic
rebound were excluded in order to exclude rebound due to simple
treatment discontinuation. Percent dose adherence was defined as
MEMS events/prescribed number of doses6100. We character-
ized patterns of missed doses by several a priori measures: (1)
number of days without a dose, defined as drug discontinuation for
more than 24 hours and less than 48 hours; (2) number of
treatment interruptions lasting $48 hours, and (3) the duration of
the longest treatment interruption (in days).
Statistical Analysis
Continuous variables were summarized as means, medians,
standard deviations and ranges. Dichotomous data were summa-
rized as proportions. Rates were compared by Fisher exact test
and continuous variable were compared by t-test. The effect of
adherence on the probability of virologic rebound was estimated
by calculating the exact odds ratios (ORs) and their 95%
confidence intervals using univariate exact conditional logistic
models, to account for the small sample size with sparse data[11].
Goodness of fit was assessed by the Farrington test for sparse data
(GOFLOGIT SAS macro). A logistic regression model curve was
used to estimate the relationship between treatment interruption
duration and the probability of virologic rebound.
We conducted a sensitivity analysis limited to subjects with
,80% adherence in order: (1) to create a closer balance in the
distribution of adherence between the groups with and without
virologic rebound, since all the subjects in the former group had
,80% adherence; and (2) to test whether adherence patterns still
predicted viral rebound at low-to-moderate adherence. Quantita-
tive variables were compared between groups with and without
virologic rebound by exact Wilcoxon two-sample non-parametric
tests because of the uncertainty of whether the small sample met
assumptions of a normal distribution.
Analyses were performed using PowerView 2.3.3 (AARDEX
Ltd, Switzerland) and SAS version 9.1 (SAS Institute Inc, Cary,
NC). All reported P values are 2-sided, and P,.05 was considered
significant.
Results
Study population
Seventy-two participants met eligibility criteria. By design, all
subjects had a HIV RNA less than 400 copies/ml during at least 3
months of NNRTI-based antiretroviral therapy. Five subjects
experienced virologic rebound. Other antiretroviral agents
included zidovudine plus lamivudine in 33 (46%), tenofovir plus
lamivudine or emtricitabine in 18 (25%), abacavir plus lamivudine
in 5 (7%), other nucleosides without protease inhibitors in 11
(15%) and ritonavir-boosted protease Inhibitors in 5 (7%). The
mean (SD) duration of MEMS monitoring in days among subjects
with and without virologic rebound were 85 (6) and 88 (6) days,
respectively. Other baseline characteristics were similar between
groups (Table 1).
Predictors of virologic rebound
All adherence measurements significantly predicted virologic
rebound, except the frequency of short-term interruptions (24 to
48 hours), as shown in Table 2. All explanatory models
demonstrated good statistical fit with virologic rebound. The
probability of virologic control according to the longer durations
of treatment interruption is displayed in Figure 1. Based on our
logistic model, a treatment interruption of 15 days was associated
with a 50% probability (95% CI=15%, 86%) of virologic rebound
(Figure 1). Figure 2 shows the relationship between average
adherence and the longer durations of treatment interruption in
days. Not surprisingly, subjects with .80% average adherence
also had short treatment interruptions and all of them achieved
virologic control.
Table 1. Baseline characteristics by study groups.
Virologic
rebound (n=5)
Virologic
control (n=67)
P
value*
Age, y (SD) 47.0 (6,3) 46.8 (10.6) 0.97
Male, No (%) 5 (100) 56 (84) 1.0
Cohort, No (%)
POSOVIR 2 (40) 50 (75) 0.13
REACH 3 (60) 17 (25)
Race, No (%)
Caucasian 4 (75) 61 (91) 0.41
Black 1 (25) 6 (9)
CD4 cell count, mean (SD) 478 (310) 532 (223) 0.62
CD4 cell nadir, mean (SD) 188 (139) 233 (175) 0.57
Prior exposure to NNRTI in
months, mean (SD)
28.4 (22.9) 30,5 (28,0) 0.88
Prior suboptimal nucleoside
exposure, No (%)
1 (20) 24 (36) 0.48
Current NNRTI, No (%)
Nevirapine 4 (80) 56 (84) 1.0
Efavirenz 1 (20) 11 (16)
Daily dosage, No (%)
Once-daily 2 (40) 27 (40) 1.0
Twice daily 3 (60) 40 (60)
*Exact Fisher chi-square test for percentages and t-test for continuous variables.
doi:10.1371/journal.pone.0002783.t001
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In the sensitivity analysis limited to subjects with low-to-
moderate (,80%) adherence, the mean difference in longest
interruption between those with and without viral rebound was
10.1 days (16.2 vs 6.1, respectively) and statistically significant
(p,0.02); whereas, the mean difference in adherence between
those with and without viral rebound was 2.8% (53.1% vs 55.9%,
respectively) and was not statistically significant (p=0.65).
(Figure 2). There were no other differences in patterns of
adherence between the two groups (data not shown).
Discussion
These data suggest that sustained and repeated NNRTI
treatment interruptions are associated with viral rebound.
Specifically, sustained treatment interruptions more closely
predicted viral rebound than interspersed missed doses in patients
with low-to-moderate adherence, which represented 24% of our
sample. Average adherence and the potential duration of
treatment interruptions are, of course, not independent; 100%
adherence precludes an interruption in treatment. As adherence
rates decline, however, different patterns of missed doses are
possible, as shown in Figure 2. Missed doses can either occur as
sustained interruptions or more regularly interspersed missed
doses. Our data suggest that not all missed doses are the same. In
particular, sustained interruptions of NNRTI-based antiretroviral
therapy are more closely associated with viral rebound than the
same number of regularly interspersed missed doses among
individuals with ,80% adherence.
Our finding derived from ‘‘real life’’ treatment interruptions in
socio-economically and ethnically diverse patients is consistent
with both observational and experimental studies of treatment
Figure 1. Predicted and observed risk of viral control according to the longer interval of treatment discontinuation, POSOVIR and
REACH cohorts.
doi:10.1371/journal.pone.0002783.g001
Table 2. Effect of adherence rates and patterns on the risk of virologic rebound.
Controls (n=67) Cases (n=5) OR* [95% CI] P value
Percentage adherence rate
1, mean (SD) 88.5 (2.2) 53.1 (7.3) 0.56 [0.37–0.81] ,0.002
No. of days without dose
$, mean (SD) 2.1 (0.4) 5.0 (1.4) 1.15 [0.94–1.40] 0.16
No. of TI
&, mean (SD) 1.2 (0.3) 8.0 (2.7) 1.38 [1.13–1.77] ,0.002
Longest interval w/o dose, mean in days (SD) 1.5 (0.4) 16.2 (3.9) 1.34 [1.15–1.68] ,0.0001
*OR [95% CI]: Odds Ratio [95% confidence Interval] computed by conditional exact logistic regression. OR.1 means an increased probability of viral rebound.
1OR and 95% CI are provided for a 10% increase in adherence rate.
$Days without dose defined as drug discontinuations for more than 24 hours and less than 48 hours.
&TI: Treatment interruptions defined as drug discontinuations for more than 48 hours.
doi:10.1371/journal.pone.0002783.t002
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defined treatment interruptions with a mean of 11.5 days were
associated with NNRTI resistance in Uganda[12]. In two trials,
Dybul and colleagues found that repeated long cycles of 4-week off
8-week-on of efavirenz-based therapy was associated with
resistance failure[13] while repeated short cycles of 1-week off 1-
week-on was not associated with failure[14], even though the 4–8
week schedule delivered more medication over time than that 1–1
week schedule (67% vs 50%, respectively). Similarly, Cohen et al.
found that virologic rebound was uncommon among an NNRTI-
treated patients with repeated short cycles of 5-days on and 2-days
off [15]. Our estimate of 50% probability of viral rebound
occurring at 15 days is consistent with these data as well as
pharmacokinetic data indicating that efavirenz clearance leads to
drug levels that allow for viral replication in 5.8 to 14 days after
discontinuation [16].
There are several limitations to our study. The number of events
(five) is small, mainly because MEMS technology is not routinely
used and because the risk of virologic rebound subsequent to viral
suppression on NNRTI-based antiretroviral therapy is low[17].
Larger studies will be needed to confirm our results. Our
observational design does not demonstrate causality and we did
not measure drug-resistance. However, the risk of resistance after
rebound on NNRTI-based therapy is predictably high [13,18–20].
In contrast to structured treatment interruption trials, our study
represents the distribution of ‘‘unstructured’’ interruptions common
in routine practice. Finally, the result may have been different in a
fully antiretroviral naı ¨ve population with ongoing viral replication.
Gross et al. found that patients treated with efavirenz-based
regimens had suboptimal adherence up to 90 days prior to viral
rebound[21]. Our data suggest that patterns of incomplete
adherence, namely interruptions in treatment, may narrow this
window. In particular, a treatment interruption of 15 days
conferred a 50% probability of virologic rebound (Figure 1).
Moreover, any treatment interruption of .7 days had a sensitivity
of 100% and a specificity of 94% to detect subsequent viral
rebound (Figure 2). Thus, the window of opportunity to intervene
on risky adherence may depend not only on the level but pattern
of adherence.
In summary, near perfect adherence leading to sustained
virologic suppression remains the goal of HIV therapy. However,
patients with moderate adherence to NNRTIs-based regimens can
still achieve virologic control. For these patients with incomplete
adherence, missing doses over a continuous and sustained interval
may pose more risk for virologic rebound than interspersed missed
doses. Limiting sustained NNRTI treatment interruptions may
improve durable virologic suppression, especially in patients with
incomplete adherence.
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